英文名稱 | Ponatinib | AP24534 |
---|---|
中文名稱 | 普納替尼 | 帕納替尼 | 泊那替尼 |
CAS號 | 943319-70-8 |
分子式 | C29H27F3N6O |
分子量 | 532.56 |
熔點(diǎn) | >160 °C |
外觀 | Light yellow to yellow powder |
儲存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
英文名稱 | Ponatinib | AP24534 |
---|---|
中文名稱 | 普納替尼 | 帕納替尼 | 泊那替尼 |
CAS號 | 943319-70-8 |
分子式 | C29H27F3N6O |
分子量 | 532.56 |
熔點(diǎn) | >160 °C |
外觀 | Light yellow to yellow powder |
儲存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
PMID: 21482694 PMCID: PMC3236248 DOI: 10.1158/1535-7163.MCT-10-1044
PMID: 19878872 PMCID: PMC2804470 DOI: 10.1016/j.ccr.2009.09.028
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
PMID: 24486648 DOI: 10.1016/j.exphem.2014.01.009